{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:17:51Z","timestamp":1778570271457,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pep.2026.106926","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:07:51Z","timestamp":1774883271000},"page":"106926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preparation and evaluation of Escherichia coli-derived glycoprotein E for development of a subunit vaccine against varicella-zoster virus"],"prefix":"10.1016","volume":"241","author":[{"given":"Luyao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pep.2026.106926_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26041132","article-title":"Advances and perspectives in the management of varicella-zoster virus infections","volume":"26","author":"Andrei","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.pep.2026.106926_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13070596","article-title":"Herpes Zoster and post-herpetic neuralgia\u2014diagnosis, treatment, and vaccination strategies","volume":"13","author":"Lim","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.pep.2026.106926_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/ITT.S176383","article-title":"Varicella zoster virus vaccines: an update","volume":"8","author":"Gabutti","year":"2019","journal-title":"ImmunoTargets Ther."},{"issue":"15","key":"10.1016\/j.pep.2026.106926_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00305-19","article-title":"The effect of age on the immunogenicity of the live attenuated zoster vaccine is predicted by baseline regulatory T cells and varicella-zoster virus-specific T cell immunity","volume":"93","author":"Weinberg","year":"2019","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.pep.2026.106926_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/v13102018","article-title":"Recent issues in varicella-Zoster virus latency","volume":"13","author":"Kennedy","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.pep.2026.106926_bib6","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1128\/JVI.01902-10","article-title":"Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis","volume":"85","author":"Zerboni","year":"2011","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01650-24","article-title":"The gE\/gI complex is necessary for kinesin-1 recruitment during alphaherpesvirus egress from neurons","volume":"99","author":"Diwaker","year":"2025","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib9","article-title":"Immunogenicity and cellular response of a Herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"15","key":"10.1016\/j.pep.2026.106926_bib10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2019.02.048","article-title":"Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice","volume":"37","author":"Wui","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.pep.2026.106926_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12070775","article-title":"Comparison of the immunogenicity of the LZ901 vaccine and HZ\/su vaccine in a mouse model","volume":"12","author":"Quan","year":"2024","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-62800-z","article-title":"Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for Herpes zoster in adults \u226550 years of age: a randomised, active-controlled, non-inferiority trial","volume":"16","author":"Jin","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41541-024-00865-5","article-title":"Potent and long-lasting humoral and cellular immunity against Varicella zoster virus induced by mRNA-LNP vaccine","volume":"9","author":"Bhattacharya","year":"2024","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.pep.2026.106926_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9040310","article-title":"Immunogenicity of Varicella-zoster virus glycoprotein E formulated with lipid nanoparticles and nucleic immunostimulators in mice","volume":"9","author":"Cao","year":"2021","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.pep.2026.106926_bib15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/21645515.2017.1317410","article-title":"A critical appraisal of \u2018Shingrix\u2019, a novel herpes zoster subunit vaccine (HZ\/Su or GSK1437173A) for Varicella zoster virus","volume":"13","author":"Bharucha","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"23","key":"10.1016\/j.pep.2026.106926_bib16","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1074\/jbc.M116.721746","article-title":"Global mapping of O-Glycosylation of Varicella Zoster virus, human cytomegalovirus, and epstein-barr Virus","volume":"291","author":"Bagdonaite","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.pep.2026.106926_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040954","article-title":"Recombinant glycoprotein E of Varicella zoster virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures","volume":"20","author":"Nord\u00e9n","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pep.2026.106926_bib18","series-title":"Varicella-Zoster Virus","first-page":"25","article-title":"The structures and functions of VZV glycoproteins","author":"Oliver","year":"2021"},{"key":"10.1016\/j.pep.2026.106926_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107831","article-title":"Factors affecting the quality of therapeutic proteins in recombinant Chinese hamster ovary cell culture","volume":"54","author":"Ha","year":"2022","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jviromet.2011.04.014","article-title":"Recombinant glycoprotein E produced in Mammalian cells in large-scale as an antigen for varicella-zoster-virus serology","volume":"175","author":"Thomsson","year":"2011","journal-title":"J. Virol. Methods"},{"issue":"4","key":"10.1016\/j.pep.2026.106926_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11427-022-2264-1","article-title":"Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design","volume":"66","author":"Chen","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"24","key":"10.1016\/j.pep.2026.106926_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01641-20","article-title":"Identification and characterization of CD4(+) T cell epitopes after shingrix vaccination","volume":"94","author":"Voic","year":"2020","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.pep.2026.106926_bib23","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.pep.2026.106926_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/(SICI)1097-0290(19990205)62:3<301::AID-BIT6>3.0.CO;2-W","article-title":"High yield refolding and purification process for recombinant human interleukin-6 expressed in Escherichia coli","volume":"62","author":"Ejima","year":"1999","journal-title":"Biotechnol. Bioeng."},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00619-9","article-title":"Design of a stabilized non-glycosylated Pfs48\/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine","volume":"8","author":"Dickey","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.pep.2026.106926_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1282016","article-title":"Non-glycosylated G protein with CpG ODN provides robust protection against respiratory syncytial virus without inducing eosinophilia","volume":"14","author":"Kawahara","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.pep.2026.106926_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9080928","article-title":"Recombinant antigens based on non-glycosylated regions from RBD SARS-CoV-2 as potential vaccine candidates against COVID-19","volume":"9","author":"N\u00fa\u00f1ez-Mu\u00f1oz","year":"2021","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.pep.2026.106926_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7030112","article-title":"An attenuated zika virus encoding non-glycosylated envelope (E) and non-structural protein 1 (NS1) confers complete protection against lethal challenge in a mouse model","volume":"7","author":"Annamalai","year":"2019","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.pep.2026.106926_bib29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1017\/S003118200100110X","article-title":"Immunogenic properties of the Plasmodium vivax vaccine candidate MSP119 expressed as a secreted non-glycosylated polypeptide from Pichia pastoris","volume":"124","author":"Soares","year":"2002","journal-title":"Parasitology"},{"issue":"11","key":"10.1016\/j.pep.2026.106926_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29112676","article-title":"Non-glycosylated SARS-CoV-2 omicron BA.5 receptor binding domain (RBD) with a native-like conformation induces a robust immune response with potent neutralization in a mouse model","volume":"29","author":"Wongnak","year":"2024","journal-title":"Molecules"},{"issue":"sup1","key":"10.1016\/j.pep.2026.106926_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4161\/hv.7.0.14586","article-title":"A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human Primates fromB. anthracisspore challenge","volume":"7","author":"Mett","year":"2014","journal-title":"Hum. Vaccines"},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145920","article-title":"MUC1 vaccines, comprised of glycosylated or non-glycosylated peptides or tumor-derived MUC1, can circumvent immunoediting to control tumor growth in MUC1 transgenic mice","volume":"11","author":"Lakshminarayanan","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pep.2026.106926_bib33","article-title":"Structures of the Varicella Zoster virus Glycoprotein E and epitope mapping of vaccine-elicited antibodies","volume":"12","author":"Harshbarger","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.pep.2026.106926_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1086\/421277","article-title":"Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus","volume":"190","author":"Vossen","year":"2004","journal-title":"J. Infect. Dis."}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592826000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592826000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:01:07Z","timestamp":1778569267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592826000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"alternative-id":["S1046592826000495"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2026.106926","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preparation and evaluation of Escherichia coli-derived glycoprotein E for development of a subunit vaccine against varicella-zoster virus","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2026.106926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106926"}}